The funding is part of a $200 million CEPI program to advance the development of vaccines that provide protection against COVID-19 variants.

The oral COVID-19 vaccine developed by Israel's Oramed Pharmaceuticals will be taken by 24 unvaccinated volunteers this month.

MigVax is ready to begin human clinical trials with its oral vaccine and is on track to market it as a booster in the next year.